Predictive oncology announces results of charter amendment proposal at special meeting

Minneapolis, aug. 18, 2021 (globe newswire) -- predictive oncology (nasdaq: poai), a knowledge-driven company focused on applying artificial intelligence (“ai”) to personalized medicine and drug discovery, announced today that on august 17, 2021, the stockholders approved an amendment to the company's certificate of incorporation to increase the number of authorized shares of company common stock from 100,000,000 to 200,000,000, and the amendment became effective on august 17, 2021. the approval was granted at the special meeting of stockholders convened on august 10, 2021 and adjourned to august 17, 2021.
POAI Ratings Summary
POAI Quant Ranking